T Altwegg

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

Xavier Pivot, Gilles Romieu, Marc Debled et al. · The Lancet · 2019 · 128 citations

Medicine, Oncology, Breast Oncology +9

Population-based study of breast cancer survival in Cote d’Or (France): prognostic factors and relative survival

Franck Bonnetain, Patrick Roignot, Marie‐Laure Poillot et al. · Annals of Oncology · 2007 · 50 citations

Medicine, Biostatistics, Oncology +15

In breast cancer, are treatments and survival the same whatever a patient's age? A population‐based study over the period 1998–2009

Pegdwendé Olivia Dialla, Valérie Quipourt, Julie Gentil et al. · Geriatrics and gerontology international/Geriatrics & gerontology international · 2014 · 19 citations · Full text

Medicine, Geriatric Medicine, Oncology +17

Population-based study of ovarian cancer in Côte d'Or: prognostic factors and trends in relative survival rates over the last 20 years

Zeinab Hamidou, Sylvain Causeret, Julie Gentil et al. · BMC Cancer · 2010 · 15 citations · Full text

Medicine, Biostatistics, Oncology +17